<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01162486</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-NCHHSTP-5779</org_study_id>
    <nct_id>NCT01162486</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers</brief_title>
  <acronym>TBTC S29B</acronym>
  <official_title>Phase I Dose Escalation Study of the Pharmacokinetics, Safety and Tolerability of Rifapentine and the Effects of Increasing Doses of Rifapentine on Induction of Metabolizing Enzymes in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate (1) the safety and tolerability of escalating doses of
      rifapentine (RPT) administered daily by oral; (2) the effect of increasing doses of RPT on
      cytochrome P450 isoform 3A (CYP3A) enzyme metabolizing activity, using single-dose midazolam
      (MDZ); and (3) the effect of increasing doses of RPT on autoinduction of RPT metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On day 1, volunteers will receive a single dose of MDZ dosed at 15 mg delivered orally, and a
      24-hour PK analysis of MDZ and its metabolite, 1-OH-midazolam (1-OH-MDZ) will be performed.
      RPT (or RIF) will be given as a single daily dose (5, 10, 15, or 20 mg/kg, depending on the
      dose cohort) on days 2-15 (14 doses). A 24-hour PK analysis of RPT (or RIF) and its
      25-deacetyl metabolite (25-des-RPT) will be performed after the first dose (day 2). On day
      15, volunteers receive a second single dose of MDZ. A 72-hour RPT (or RIF) and 24-hour MDZ
      (and 1-OH-MDZ) PK analysis will be performed after the second dose of MDZ beginning on day
      15. The PK sampling will occur both on an in-patient basis in the General Clinical Research
      Center (GCRC) and on an out-patient basis in the study clinic. Volunteers will undergo
      assessments for adverse events (AEs) several times throughout the study.

      Each dose cohort will contain 6 subjects. RPT dosing will begin at 5 mg/kg (6 volunteers) and
      increase by 5 mg/kg increments (6 volunteers each at 10, 15, and 20 mg/kg) to a maximum dose
      of 20 mg/kg unless dose-limiting toxicities (DLT) are seen in two or more patients within a
      dose cohort, in which case a dose that is 2.5 mg/kg lower than the previous dose will be
      enrolled to determine the maximal tolerated dose (MTD). In addition, one cohort of 6 subjects
      will receive RIF at 10 mg/kg daily, rather than RPT, as a comparator arm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>days: 3, 7, 10, 14, 15, 17, 26</time_frame>
    <description>To determine the safety of escalating doses, from 5 mg/kg to 20 mg/kg of daily rifapentine administered orally for 14 days in healthy volunteers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>days: 2, 3, 7, 10, 15, 16, 17, 18</time_frame>
    <description>To determine and compare the steady-state pharmacokinetics and dose linearity of escalating daily doses of rifapentine in dose cohorts of 5 mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kg in healthy volunteers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>autoinduction</measure>
    <time_frame>days: 2, 3, 7, 10, 15, 16, 17, 18</time_frame>
    <description>To evaluate for evidence of autoinduction of metabolism by rifapentine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>midazolam</measure>
    <time_frame>days: 1, 15</time_frame>
    <description>To compare and describe, the pharmacokinetics of single-dose midazolam alone versus midazolam co-administered with either steady-state rifapentine at multiple daily doses (5, 10, 15, and 20 mg/kg) or rifampin at 10 mg/kg daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transporter genes</measure>
    <time_frame>day 3</time_frame>
    <description>To determine the effects of polymorphisms of transporter genes on rifampin and rifapentine PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dried blood spots</measure>
    <time_frame>days 2, 3, 7, 10, 15, 16, 17, 18</time_frame>
    <description>To develop methods for determination of rifapentine concentrations from dried blood spots on sampling paper</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Tuberculosis</condition>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Rifampin control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rifampin + midazolam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RPT 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RPT Cohort 1 - 5 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RPT 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RPT Cohort 2 - 10 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RPT 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RPT Cohort 3 - 15 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RPT 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RPT Cohort 4 - 20 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RPT 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RPT Cohort 5 - Maximal tolerated dose, if dose limiting toxicities are observed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin &amp; midazolam</intervention_name>
    <description>rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15</description>
    <arm_group_label>Rifampin control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifapentine &amp; midazolam</intervention_name>
    <description>rifapentine - tablet, 5 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15</description>
    <arm_group_label>RPT 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifapentine &amp; midazolam</intervention_name>
    <description>rifapentine - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15</description>
    <arm_group_label>RPT 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifapentine &amp; midazolam</intervention_name>
    <description>rifapentine - tablet, 15 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15</description>
    <arm_group_label>RPT 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifapentine and midazolam</intervention_name>
    <description>rifapentine - tablet, 20 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15</description>
    <arm_group_label>RPT 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifapentine and midazolam</intervention_name>
    <description>rifapentine - tablet, 2.5 mg/kg lower than previously tolerated dose cohort, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15</description>
    <arm_group_label>RPT 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability and willingness to provide written informed consent.

          2. Age greater than or equal to 18 years, and less than or equal to 65 years.

          3. Weight of 50-100 kg for enrollment into the RPT cohorts

          4. Weight of 50-80 kg for enrollment into the RIF cohort

          5. Within 28 or fewer days prior to enrollment, a complete blood count with differential,
             comprehensive serum chemistry profile, HIV antibody test, and Hepatitis C antibody
             test will be performed, with the following laboratory values:

               1. Serum amino aspartate transferase (AST) less than the upper limit of normal

               2. Total bilirubin level less than the upper limit of normal

               3. Serum creatinine &lt;1.5 mg/dL

               4. Hemoglobin greater than 12.0 for men, greater than 11.0 for women

               5. Platelet count greater than or equal to 125,000 /cu mm

               6. Absolute neutrophil count greater than or equal to 1250 /cu mm

               7. Serum albumin greater than 3.5 g/dL

               8. HIV antibody test negative

               9. Hepatitis C antibody negative

          6. For women of childbearing potential, a negative serum bHCG pregnancy test, performed
             at screening.

          7. During the study and for 14 days after the last dose of study medication, women of
             childbearing potential must agree to practice barrier contraception for the duration
             of the study.

        Exclusion Criteria:

          1. Pregnant or breastfeeding

          2. Known intolerance of or allergy to rifamycins

          3. Allergy to benzodiazepines

          4. Use of rifamycin antibiotics in the 30 days prior to enrollment

          5. Inability to take oral medications

          6. Renal, hepatic, cardiac (except benign heart murmur), or endocrine disorder; or
             malignancy; or immunocompromise.

          7. History of any acute or chronic illness that requires current medical therapy.

          8. Prior gastrointestinal surgery involving stomach, biliary system, pancreas, or small
             intestine.

          9. Any medical condition that, in the opinion of the investigator, would interfere with
             the subject's ability to participate in the protocol.

         10. Any illicit drug use within the preceding 2 months. Subjects must agree to abstain
             from alcohol and illicit drug use during the study. Smokers must agree to abstain from
             cigarettes or to smoke fewer than 5 cigarettes per day.

         11. Current use of any prescription medication(s), including oral contraceptives.

         12. Planned use, during the study from Day 0 through the last PK blood draw, of any of the
             following: prescription medication(s), herbal supplement(s), vitamin(s), mineral
             supplement(s), over-the-counter medication(s), or grapefruit juice. Subjects must
             agree to abstain from grapefruit juice during the study.

         13. Participation in any other investigational drug study within 30 days prior to study
             entry and during study.

         14. Inability to participate in pharmacokinetic visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly Dooley, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Dorman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Univeristy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2010</study_first_submitted>
  <study_first_submitted_qc>July 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2010</study_first_posted>
  <last_update_submitted>April 1, 2013</last_update_submitted>
  <last_update_submitted_qc>April 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Susan E. Dorman</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Anti-infective agents</keyword>
  <keyword>Anti-bacterial agents</keyword>
  <keyword>Rifampin</keyword>
  <keyword>Rifapentine</keyword>
  <keyword>Midazolam</keyword>
  <keyword>Molecular mechanisms of pharmacological action</keyword>
  <keyword>Antitubercular agents</keyword>
  <keyword>Pharmacologic actions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Rifapentine</mesh_term>
    <mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 20, 2014</submitted>
    <returned>November 24, 2014</returned>
    <submitted>February 22, 2016</submitted>
    <returned>March 22, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

